DK2651416T3 - RELATIONSHIPS USED FOR TREATMENT OF AIDS - Google Patents
RELATIONSHIPS USED FOR TREATMENT OF AIDS Download PDFInfo
- Publication number
- DK2651416T3 DK2651416T3 DK11805230.7T DK11805230T DK2651416T3 DK 2651416 T3 DK2651416 T3 DK 2651416T3 DK 11805230 T DK11805230 T DK 11805230T DK 2651416 T3 DK2651416 T3 DK 2651416T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- hydrogen atom
- nrarb
- chloro
- methyl
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 19
- 238000011282 treatment Methods 0.000 title claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 174
- 150000001875 compounds Chemical class 0.000 claims abstract description 141
- 229910003827 NRaRb Inorganic materials 0.000 claims abstract description 66
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 229910052801 chlorine Chemical group 0.000 claims abstract description 28
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 26
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 12
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims abstract description 5
- 125000003709 fluoroalkyl group Chemical group 0.000 claims abstract description 5
- 125000005843 halogen group Chemical group 0.000 claims abstract description 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 108
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 22
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- -1 2 - (8-chloro-3-methyl-5- (2- (piperidin-1-yl) ethoxy) quinolin-2-yl) -4-methylpyridine-2,3 -diamine Chemical compound 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 229940095064 tartrate Drugs 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- VFTVHCSXVHUNNI-UHFFFAOYSA-N 8-chloro-5-(2-piperidin-1-ylethoxy)-n-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound FC(F)(F)C1=CC=NC(NC=2N=C3C(Cl)=CC=C(OCCN4CCCCC4)C3=CC=2)=C1 VFTVHCSXVHUNNI-UHFFFAOYSA-N 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 4
- 229940072107 ascorbate Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 4
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 claims description 3
- LWHIWNYBTZRFEP-UHFFFAOYSA-N 2-[(3-amino-4-methylpyridin-2-yl)amino]-5-(dimethylsulfamoylamino)-3-methylquinoline Chemical compound CC=1C=C2C(NS(=O)(=O)N(C)C)=CC=CC2=NC=1NC1=NC=CC(C)=C1N LWHIWNYBTZRFEP-UHFFFAOYSA-N 0.000 claims description 3
- DEOZHEHMTWAECR-UHFFFAOYSA-N 2-[(3-amino-4-methylpyridin-2-yl)amino]-8-chloro-5-(dimethylsulfamoylamino)-3-methylquinoline Chemical compound CC=1C=C2C(NS(=O)(=O)N(C)C)=CC=C(Cl)C2=NC=1NC1=NC=CC(C)=C1N DEOZHEHMTWAECR-UHFFFAOYSA-N 0.000 claims description 3
- STCNAZVMTAVEOZ-UHFFFAOYSA-N 2-[(3-amino-4-methylpyridin-2-yl)amino]-8-chloro-5-(dimethylsulfamoylamino)quinoline Chemical compound C=1C=C2C(NS(=O)(=O)N(C)C)=CC=C(Cl)C2=NC=1NC1=NC=CC(C)=C1N STCNAZVMTAVEOZ-UHFFFAOYSA-N 0.000 claims description 3
- FLGXDPRMCBJQQN-UHFFFAOYSA-N 2-[3-chloro-4-(trifluoromethoxy)anilino]-5-(dimethylsulfamoylamino)-3-methylquinoline Chemical compound CC=1C=C2C(NS(=O)(=O)N(C)C)=CC=CC2=NC=1NC1=CC=C(OC(F)(F)F)C(Cl)=C1 FLGXDPRMCBJQQN-UHFFFAOYSA-N 0.000 claims description 3
- UCRMMFCBPWUBIE-UHFFFAOYSA-N 2-n-(3-amino-4-methylpyridin-2-yl)-8-chloro-3-methylquinoline-2,5-diamine Chemical compound CC1=CC=NC(NC=2C(=CC3=C(N)C=CC(Cl)=C3N=2)C)=C1N UCRMMFCBPWUBIE-UHFFFAOYSA-N 0.000 claims description 3
- FPXYLXAMMKEESV-UHFFFAOYSA-N 2-n-[8-chloro-5-(2-morpholin-4-ylethoxy)quinolin-2-yl]-4-methylpyridine-2,3-diamine Chemical compound CC1=CC=NC(NC=2N=C3C(Cl)=CC=C(OCCN4CCOCC4)C3=CC=2)=C1N FPXYLXAMMKEESV-UHFFFAOYSA-N 0.000 claims description 3
- SHPNFUONBHWVSI-UHFFFAOYSA-N 8-chloro-2-[3-chloro-4-(trifluoromethoxy)anilino]-5-(dimethylsulfamoylamino)quinoline Chemical compound C=1C=C2C(NS(=O)(=O)N(C)C)=CC=C(Cl)C2=NC=1NC1=CC=C(OC(F)(F)F)C(Cl)=C1 SHPNFUONBHWVSI-UHFFFAOYSA-N 0.000 claims description 3
- AFAFQKALERZORJ-UHFFFAOYSA-N 8-chloro-3-methyl-5-(2-piperidin-1-ylethoxy)-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(Cl)=C2N=C(NC=3C=CC(OC(F)(F)F)=CC=3)C(C)=CC2=C1OCCN1CCCCC1 AFAFQKALERZORJ-UHFFFAOYSA-N 0.000 claims description 3
- SGTKQHGNCBULSG-UHFFFAOYSA-N 8-chloro-3-methyl-5-(2-piperidin-1-ylethoxy)-n-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound C1=CC(Cl)=C2N=C(NC=3N=CC=C(C=3)C(F)(F)F)C(C)=CC2=C1OCCN1CCCCC1 SGTKQHGNCBULSG-UHFFFAOYSA-N 0.000 claims description 3
- ULCABPKCNGZGAZ-UHFFFAOYSA-N 8-chloro-n-(3-chloro-4-methoxyphenyl)-5-(2-morpholin-4-ylethoxy)quinolin-2-amine Chemical compound C1=C(Cl)C(OC)=CC=C1NC1=CC=C(C(OCCN2CCOCC2)=CC=C2Cl)C2=N1 ULCABPKCNGZGAZ-UHFFFAOYSA-N 0.000 claims description 3
- IICKDKFFDMYJSX-UHFFFAOYSA-N 8-chloro-n-[4-methoxy-3-(2-morpholin-4-ylethoxy)phenyl]quinolin-2-amine Chemical compound COC1=CC=C(NC=2N=C3C(Cl)=CC=CC3=CC=2)C=C1OCCN1CCOCC1 IICKDKFFDMYJSX-UHFFFAOYSA-N 0.000 claims description 3
- IDQIZEYRBHTFBR-UHFFFAOYSA-N 8-chloro-n-[4-methoxy-3-(2-piperidin-1-ylethoxy)phenyl]quinolin-2-amine Chemical compound COC1=CC=C(NC=2N=C3C(Cl)=CC=CC3=CC=2)C=C1OCCN1CCCCC1 IDQIZEYRBHTFBR-UHFFFAOYSA-N 0.000 claims description 3
- SZNXWCCWQXCTNP-UHFFFAOYSA-N 8-chloro-n-[4-methoxy-3-[2-(2-methoxyethoxy)ethoxy]phenyl]quinolin-2-amine Chemical compound C1=C(OC)C(OCCOCCOC)=CC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 SZNXWCCWQXCTNP-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- GTEQYEMPPBFZQT-UHFFFAOYSA-N n-[3-methyl-2-[[4-(trifluoromethyl)pyridin-2-yl]amino]quinolin-5-yl]methanesulfonamide Chemical compound CC1=CC2=C(NS(C)(=O)=O)C=CC=C2N=C1NC1=CC(C(F)(F)F)=CC=N1 GTEQYEMPPBFZQT-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- QJRSHFGNVORSNK-UHFFFAOYSA-N 8-chloro-5-(2-morpholin-4-ylethoxy)-n-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound FC(F)(F)C1=CC=NC(NC=2N=C3C(Cl)=CC=C(OCCN4CCOCC4)C3=CC=2)=C1 QJRSHFGNVORSNK-UHFFFAOYSA-N 0.000 claims 2
- GTIAINXNOUGZHA-UHFFFAOYSA-N 8-chloro-5-(2-piperidin-1-ylethoxy)-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C(OCCN2CCCCC2)=CC=C2Cl)C2=N1 GTIAINXNOUGZHA-UHFFFAOYSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- ANOKSOJDHQMKIW-UHFFFAOYSA-N quinoline-2,5-diamine Chemical compound NC1=CC=CC2=NC(N)=CC=C21 ANOKSOJDHQMKIW-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 11
- 125000000217 alkyl group Chemical group 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 229910006069 SO3H Inorganic materials 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- 239000011541 reaction mixture Substances 0.000 description 47
- 230000002829 reductive effect Effects 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- 229940093499 ethyl acetate Drugs 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- 239000000203 mixture Substances 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 10
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 7
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- HRHZGVIXTTVSBL-UHFFFAOYSA-N 2-chloro-5-(2-piperidin-1-ylethoxy)aniline Chemical compound C1=C(Cl)C(N)=CC(OCCN2CCCCC2)=C1 HRHZGVIXTTVSBL-UHFFFAOYSA-N 0.000 description 4
- UWZBOFHBRKLFLJ-UHFFFAOYSA-N 4-[2-(4-chloro-3-nitrophenoxy)ethyl]piperidine Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(OCCC2CCNCC2)=C1 UWZBOFHBRKLFLJ-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- BJFRVAWKEPFMEK-UHFFFAOYSA-N 2,8-dichloro-5-(2-piperidin-1-ylethoxy)quinoline Chemical compound C=1C=C(Cl)C2=NC(Cl)=CC=C2C=1OCCN1CCCCC1 BJFRVAWKEPFMEK-UHFFFAOYSA-N 0.000 description 3
- JUIKCULGDIZNDI-UHFFFAOYSA-N 4-chloro-3-nitrophenol Chemical compound OC1=CC=C(Cl)C([N+]([O-])=O)=C1 JUIKCULGDIZNDI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000009830 intercalation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000003586 protic polar solvent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 2
- DKGXZFTVJFKCDM-FBMGVBCBSA-N (e)-n-[2-chloro-5-(2-piperidin-1-ylethoxy)phenyl]-2-methyl-3-phenylprop-2-enamide Chemical compound C=1C(OCCN2CCCCC2)=CC=C(Cl)C=1NC(=O)C(/C)=C/C1=CC=CC=C1 DKGXZFTVJFKCDM-FBMGVBCBSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- CDDDASADVLSBGR-UHFFFAOYSA-N 2-chloro-5-(2-morpholin-4-ylethoxy)aniline Chemical compound C1=C(Cl)C(N)=CC(OCCN2CCOCC2)=C1 CDDDASADVLSBGR-UHFFFAOYSA-N 0.000 description 2
- OKFLXXZLKOMXMO-UHFFFAOYSA-N 4-(2-chloroethyl)piperidine Chemical compound ClCCC1CCNCC1 OKFLXXZLKOMXMO-UHFFFAOYSA-N 0.000 description 2
- PVZKNIUPMZIIAR-UHFFFAOYSA-N 4-[2-(2,8-dichloroquinolin-5-yl)oxyethyl]morpholine Chemical compound C=1C=C(Cl)C2=NC(Cl)=CC=C2C=1OCCN1CCOCC1 PVZKNIUPMZIIAR-UHFFFAOYSA-N 0.000 description 2
- KJISCJBGTAILPZ-UHFFFAOYSA-N 4-[2-(2-methoxy-5-nitrophenoxy)ethyl]morpholine Chemical compound COC1=CC=C([N+]([O-])=O)C=C1OCCN1CCOCC1 KJISCJBGTAILPZ-UHFFFAOYSA-N 0.000 description 2
- FRRCWBKLOLEPGE-UHFFFAOYSA-N 4-[2-(4-chloro-3-nitrophenoxy)ethyl]morpholine Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(OCCN2CCOCC2)=C1 FRRCWBKLOLEPGE-UHFFFAOYSA-N 0.000 description 2
- BAQGLBFRBSZEOQ-UHFFFAOYSA-N 4-methoxy-3-(2-morpholin-4-ylethoxy)aniline Chemical compound COC1=CC=C(N)C=C1OCCN1CCOCC1 BAQGLBFRBSZEOQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- LLUHPWMREVBUDB-UHFFFAOYSA-N 8-chloro-3-methyl-5-(2-piperidin-1-ylethoxy)-1h-quinolin-2-one Chemical compound C1=CC(Cl)=C2NC(=O)C(C)=CC2=C1OCCN1CCCCC1 LLUHPWMREVBUDB-UHFFFAOYSA-N 0.000 description 2
- RGZQNFFYKDOYIU-UHFFFAOYSA-N 8-chloro-5-(2-morpholin-4-ylethoxy)-1h-quinolin-2-one Chemical compound C1=2C=CC(=O)NC=2C(Cl)=CC=C1OCCN1CCOCC1 RGZQNFFYKDOYIU-UHFFFAOYSA-N 0.000 description 2
- VIBUNEKIUWHDAK-UHFFFAOYSA-N 8-chloro-5-(2-piperidin-1-ylethoxy)-1h-quinolin-2-one Chemical compound C1=2C=CC(=O)NC=2C(Cl)=CC=C1OCCN1CCCCC1 VIBUNEKIUWHDAK-UHFFFAOYSA-N 0.000 description 2
- ABYPFTKEOAKNMH-UHFFFAOYSA-N 8-chloro-n-(4-methyl-3-nitropyridin-2-yl)-5-(2-morpholin-4-ylethoxy)quinolin-2-amine Chemical compound CC1=CC=NC(NC=2N=C3C(Cl)=CC=C(OCCN4CCOCC4)C3=CC=2)=C1[N+]([O-])=O ABYPFTKEOAKNMH-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 101710205625 Capsid protein p24 Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101710149279 Small delta antigen Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- JGPOSNWWINVNFV-UHFFFAOYSA-N carboxyfluorescein diacetate succinimidyl ester Chemical compound C=1C(OC(=O)C)=CC=C2C=1OC1=CC(OC(C)=O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O JGPOSNWWINVNFV-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- BLDVHVNYAUIZFO-UHFFFAOYSA-N n-[2-chloro-5-(2-morpholin-4-ylethoxy)phenyl]-3-phenylprop-2-enamide Chemical compound C1=C(NC(=O)C=CC=2C=CC=CC=2)C(Cl)=CC=C1OCCN1CCOCC1 BLDVHVNYAUIZFO-UHFFFAOYSA-N 0.000 description 2
- WCIGGRRLWDONEK-UHFFFAOYSA-N n-[2-chloro-5-(2-piperidin-1-ylethoxy)phenyl]-3-phenylprop-2-enamide Chemical compound C1=C(NC(=O)C=CC=2C=CC=CC=2)C(Cl)=CC=C1OCCN1CCCCC1 WCIGGRRLWDONEK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- XHIRBFXXIZZLNG-BQYQJAHWSA-N (e)-2-methyl-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)C(/C)=C/C1=CC=CC=C1 XHIRBFXXIZZLNG-BQYQJAHWSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- LRIVMBWLBXNWGI-UHFFFAOYSA-N 2,8-dichloro-3-methyl-5-(2-piperidin-1-ylethoxy)quinoline Chemical compound C1=CC(Cl)=C2N=C(Cl)C(C)=CC2=C1OCCN1CCCCC1 LRIVMBWLBXNWGI-UHFFFAOYSA-N 0.000 description 1
- VAXOCTXTVIVOQE-UHFFFAOYSA-N 2,8-dichloroquinoline Chemical compound C1=CC=C(Cl)C2=NC(Cl)=CC=C21 VAXOCTXTVIVOQE-UHFFFAOYSA-N 0.000 description 1
- KXKCTSZYNCDFFG-UHFFFAOYSA-N 2-Methoxy-5-nitrophenol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1O KXKCTSZYNCDFFG-UHFFFAOYSA-N 0.000 description 1
- CDRBXJDVDCNVCR-UHFFFAOYSA-N 2-[4-[(8-chloroquinolin-2-yl)amino]phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 CDRBXJDVDCNVCR-UHFFFAOYSA-N 0.000 description 1
- YSOZQQVJTPFTMQ-UHFFFAOYSA-N 2-n-[8-chloro-3-methyl-5-(2-piperidin-1-ylethoxy)quinolin-2-yl]-4-methylpyridine-2,3-diamine Chemical compound CC1=CC=NC(NC=2C(=CC3=C(OCCN4CCCCC4)C=CC(Cl)=C3N=2)C)=C1N YSOZQQVJTPFTMQ-UHFFFAOYSA-N 0.000 description 1
- BPYHGTCRXDWOIQ-UHFFFAOYSA-N 3-nitropyridin-2-amine Chemical compound NC1=NC=CC=C1[N+]([O-])=O BPYHGTCRXDWOIQ-UHFFFAOYSA-N 0.000 description 1
- MPOYBFYHRQBZPM-UHFFFAOYSA-N 3h-pyridin-4-one Chemical group O=C1CC=NC=C1 MPOYBFYHRQBZPM-UHFFFAOYSA-N 0.000 description 1
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 1
- RWGBXAQMUBGGKQ-UHFFFAOYSA-N 4-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC(C(F)(F)F)=CC=N1 RWGBXAQMUBGGKQ-UHFFFAOYSA-N 0.000 description 1
- YGWZBJQQLKWYRQ-UHFFFAOYSA-N 8-chloro-2-[3-chloro-4-(trifluoromethoxy)anilino]-5-(dimethylsulfamoylamino)-3-methylquinoline Chemical compound CC=1C=C2C(NS(=O)(=O)N(C)C)=CC=C(Cl)C2=NC=1NC1=CC=C(OC(F)(F)F)C(Cl)=C1 YGWZBJQQLKWYRQ-UHFFFAOYSA-N 0.000 description 1
- AUTPWUQQIPIRES-UHFFFAOYSA-N 8-chloro-2-n-[3-chloro-4-(trifluoromethoxy)phenyl]-3-methylquinoline-2,5-diamine Chemical compound CC1=CC2=C(N)C=CC(Cl)=C2N=C1NC1=CC=C(OC(F)(F)F)C(Cl)=C1 AUTPWUQQIPIRES-UHFFFAOYSA-N 0.000 description 1
- LMKDXRLMPNWFJO-UHFFFAOYSA-N 8-chloro-3-methyl-2-n-[4-(trifluoromethyl)pyridin-2-yl]quinoline-2,5-diamine Chemical compound CC1=CC2=C(N)C=CC(Cl)=C2N=C1NC1=CC(C(F)(F)F)=CC=N1 LMKDXRLMPNWFJO-UHFFFAOYSA-N 0.000 description 1
- JREVCPFWYFNPGG-UHFFFAOYSA-N 8-chloro-n-[3-chloro-4-(trifluoromethoxy)phenyl]-5-(2-piperidin-1-ylethoxy)quinolin-2-amine Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1NC1=CC=C(C(OCCN2CCCCC2)=CC=C2Cl)C2=N1 JREVCPFWYFNPGG-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical class N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HAVWZAULCLKNBA-UHFFFAOYSA-N n-[2-[3-chloro-4-(trifluoromethoxy)anilino]-3-methylquinolin-5-yl]methanesulfonamide Chemical compound CC1=CC2=C(NS(C)(=O)=O)C=CC=C2N=C1NC1=CC=C(OC(F)(F)F)C(Cl)=C1 HAVWZAULCLKNBA-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 125000005009 perfluoropropyl group Chemical group FC(C(C(F)(F)F)(F)F)(F)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10306417A EP2465502A1 (en) | 2010-12-15 | 2010-12-15 | Compounds useful for treating AIDS |
| PCT/IB2011/055643 WO2012080953A1 (en) | 2010-12-15 | 2011-12-13 | Compounds useful for treating aids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2651416T3 true DK2651416T3 (en) | 2018-08-06 |
Family
ID=43755105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11805230.7T DK2651416T3 (en) | 2010-12-15 | 2011-12-13 | RELATIONSHIPS USED FOR TREATMENT OF AIDS |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9061999B2 (enExample) |
| EP (2) | EP2465502A1 (enExample) |
| JP (1) | JP6049630B2 (enExample) |
| KR (1) | KR101749232B1 (enExample) |
| CN (1) | CN103415290B (enExample) |
| AR (1) | AR084277A1 (enExample) |
| AU (1) | AU2011342826B2 (enExample) |
| BR (1) | BR112013014943B1 (enExample) |
| CA (1) | CA2819317C (enExample) |
| CU (1) | CU20130080A7 (enExample) |
| DK (1) | DK2651416T3 (enExample) |
| ES (1) | ES2681539T3 (enExample) |
| HR (1) | HRP20181190T1 (enExample) |
| MX (1) | MX337258B (enExample) |
| PL (1) | PL2651416T3 (enExample) |
| PT (1) | PT2651416T (enExample) |
| RU (1) | RU2598845C2 (enExample) |
| WO (1) | WO2012080953A1 (enExample) |
| ZA (1) | ZA201303922B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102625804B (zh) | 2009-06-12 | 2015-04-08 | Abivax公司 | 用于治疗aids的化合物 |
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| CA2916623C (en) * | 2013-07-05 | 2021-09-14 | Abivax | Bicyclic compounds useful for treating diseases caused by retroviruses |
| EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059591A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| EP3337481B1 (en) | 2015-08-21 | 2020-11-11 | The University of Kansas | Quinoline-2-amine derivatives as human tlr8-selective agonists for increasing immune response |
| WO2017158201A1 (en) * | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
| KR101966351B1 (ko) * | 2016-06-08 | 2019-04-08 | 한국과학기술연구원 | 히스톤 메틸전달효소 저해용 퀴놀린 유도체 및 이의 용도 |
| US10323289B2 (en) | 2017-06-26 | 2019-06-18 | Institut Pasteur | Treatments to eliminate HIV reservoirs and reduce viral load |
| WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| CN109776498B (zh) * | 2019-03-13 | 2020-04-07 | 浙江永宁药业股份有限公司 | 一种西洛他唑的制备方法 |
| EP3999493B1 (en) | 2019-07-19 | 2023-12-20 | Abivax | Aryl-n-aryl derivatives for treating a rna virus infection |
| EP4063351A1 (en) * | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| TW202436296A (zh) * | 2022-11-25 | 2024-09-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹啉胺類化合物晶型及其製備方法 |
| WO2025027388A1 (en) | 2023-08-01 | 2025-02-06 | Abivax | Obefazimod for treatment of ulcerative colitis |
| EP4785941A1 (en) | 2025-01-31 | 2026-08-05 | Abivax | Combination of obefazimod and its derivatives with a alpha4beta7 anti-integrin |
| EP4785940A1 (en) | 2025-01-31 | 2026-08-05 | Abivax | Combination of obefazimod and its derivatives with a tnf alpha-inhibitor |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2419199A (en) * | 1945-02-09 | 1947-04-22 | Parke Davis & Co | Quinoline compounds and process of making same |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| JPS59501318A (ja) * | 1982-07-26 | 1984-07-26 | アメリカン ホスピタル サプライ コ−ポレ−シヨン | ヘテロアリ−ル置換アミノメチルベンゼン誘導体 |
| US4466965A (en) * | 1982-07-26 | 1984-08-21 | American Hospital Supply Corporation | Phthalazine compounds, compositions and use |
| FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| AU763750B2 (en) | 1999-04-05 | 2003-07-31 | City Of Hope | Novel inhibitors of formation of advanced glycation endproducts (AGE's) |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| JP2005531574A (ja) | 2002-05-22 | 2005-10-20 | アムジエン・インコーポレーテツド | 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体 |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| MXPA05000827A (es) | 2002-07-19 | 2005-08-29 | Memory Pharm Corp | Inhibidores de fosfodiesterasa 4, incluyendo analogos de anilina y difenilamina n-sustituidos. |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (en) * | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| US20100249184A1 (en) | 2007-03-16 | 2010-09-30 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| US8222634B2 (en) | 2007-05-17 | 2012-07-17 | Lg Chem, Ltd. | Anthracene derivatives and organic electronic device using the same |
| WO2009023844A2 (en) | 2007-08-15 | 2009-02-19 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-ht6 receptor affinity |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| CN102625804B (zh) | 2009-06-12 | 2015-04-08 | Abivax公司 | 用于治疗aids的化合物 |
-
2010
- 2010-12-15 EP EP10306417A patent/EP2465502A1/en not_active Withdrawn
-
2011
- 2011-12-13 CA CA2819317A patent/CA2819317C/en active Active
- 2011-12-13 CN CN201180060026.XA patent/CN103415290B/zh active Active
- 2011-12-13 EP EP11805230.7A patent/EP2651416B1/en active Active
- 2011-12-13 JP JP2013543948A patent/JP6049630B2/ja not_active Expired - Fee Related
- 2011-12-13 US US13/993,990 patent/US9061999B2/en active Active
- 2011-12-13 AU AU2011342826A patent/AU2011342826B2/en not_active Ceased
- 2011-12-13 PL PL11805230T patent/PL2651416T3/pl unknown
- 2011-12-13 ES ES11805230.7T patent/ES2681539T3/es active Active
- 2011-12-13 WO PCT/IB2011/055643 patent/WO2012080953A1/en not_active Ceased
- 2011-12-13 RU RU2013126947/04A patent/RU2598845C2/ru active
- 2011-12-13 PT PT118052307T patent/PT2651416T/pt unknown
- 2011-12-13 BR BR112013014943-4A patent/BR112013014943B1/pt active IP Right Grant
- 2011-12-13 MX MX2013006322A patent/MX337258B/es active IP Right Grant
- 2011-12-13 KR KR1020137018457A patent/KR101749232B1/ko not_active Expired - Fee Related
- 2011-12-13 HR HRP20181190TT patent/HRP20181190T1/hr unknown
- 2011-12-13 DK DK11805230.7T patent/DK2651416T3/en active
- 2011-12-14 AR ARP110104670A patent/AR084277A1/es active IP Right Grant
-
2013
- 2013-05-29 ZA ZA2013/03922A patent/ZA201303922B/en unknown
- 2013-06-13 CU CUP2013000080A patent/CU20130080A7/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140041402A (ko) | 2014-04-04 |
| ES2681539T3 (es) | 2018-09-13 |
| RU2598845C2 (ru) | 2016-09-27 |
| EP2651416A1 (en) | 2013-10-23 |
| CA2819317A1 (en) | 2012-06-21 |
| CU20130080A7 (es) | 2013-08-29 |
| JP2013545798A (ja) | 2013-12-26 |
| US20130267703A1 (en) | 2013-10-10 |
| AU2011342826A1 (en) | 2013-07-04 |
| CN103415290A (zh) | 2013-11-27 |
| PL2651416T3 (pl) | 2018-09-28 |
| BR112013014943A2 (pt) | 2016-09-13 |
| KR101749232B1 (ko) | 2017-07-03 |
| BR112013014943B1 (pt) | 2022-05-03 |
| CA2819317C (en) | 2017-02-28 |
| WO2012080953A1 (en) | 2012-06-21 |
| US9061999B2 (en) | 2015-06-23 |
| CN103415290B (zh) | 2016-09-14 |
| PT2651416T (pt) | 2018-07-30 |
| EP2651416B1 (en) | 2018-05-09 |
| JP6049630B2 (ja) | 2016-12-21 |
| ZA201303922B (en) | 2014-07-30 |
| BR112013014943A8 (pt) | 2018-06-12 |
| AR084277A1 (es) | 2013-05-02 |
| HRP20181190T1 (hr) | 2019-03-08 |
| RU2013126947A (ru) | 2015-01-20 |
| MX2013006322A (es) | 2013-10-25 |
| MX337258B (es) | 2016-02-22 |
| AU2011342826B2 (en) | 2016-02-11 |
| EP2465502A1 (en) | 2012-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2819317C (en) | Compounds useful for treating aids | |
| ES2938532T3 (es) | Nuevas moléculas químicas que inhiben el mecanismo de ayuste para el tratamiento de enfermedades derivadas de defectos de ayuste | |
| JP6606577B2 (ja) | Ａｉｄｓを治療する為に有用な化合物 | |
| EP2975034A1 (en) | A quinoline derivative for the treatment of inflammatory diseases and AIDS | |
| HK40086860A (en) | Preparation of compounds useful for treating aids | |
| RU2575845C2 (ru) | Соединения, пригодные для лечения спида |